Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Gene Therapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CCNG1 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CCNG1 Recombinant Protein (WT) High purity (>95%), Endotoxin controlled. Sequence Verified. Suitable for PPI assays. |
View CCNG1 Products |
| Gene Delivery | CCNG1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and overexpression studies. |
View CCNG1 Products |
| Benchmark Ab | Anti-CCNG1 Recombinant Antibody High-specificity positive control for Western Blot, IHC, and IP validation. |
View CCNG1 Products |
| Validator | CCNG1 siRNA Set Target-specific knockdown verification in cancer cell lines. |
View CCNG1 Products |
| Related Target A | MDM2 CCNG1 regulates p53 stability via MDM2-mediated ubiquitination; key pathway partner. |
View MDM2 Products |
| Related Target B | TP53 CCNG1 is a direct transcriptional target of p53, forming a critical feedback loop. |
View TP53 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Intracellular PPI Screening (CCNG1-MDM2 / PP2A) | High-purity, structurally verified recombinant proteins with low endotoxin levels to ensure assay reproducibility. |
| In Vitro Knockdown Validation | Sequence-verified siRNA sets to confirm target specificity and minimize off-target phenotypic effects. |
| Lack of Controls | Highly characterized recombinant antibodies available for reliable expression profiling. |
| False Positives | Strictly controlled expression systems (E. coli / Insect cells) matching theoretical molecular weights. |
Live CCNG1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CCNG1 therapeutics is intensifying, with major players shifting focus from traditional small molecules to gene therapies and RNA-targeted modalities. As first-generation therapies reach the clinic, the next wave of R&D is targeting chemoresistance pathways and synergistic combinations in refractory solid tumors.
Historically considered an atypical cyclin, CCNG1 (Cyclin G1) plays a pivotal role in the p53-MDM2 feedback loop and DNA damage response. Overexpression of CCNG1 is strongly correlated with poor prognosis and multi-drug resistance in osteosarcoma, pancreatic, breast, and colorectal cancers. The clinical validation of DeltaRex-G (a retroviral vector encoding a dominant-negative CCNG1 mutant) has paved the way for advanced gene-delivery strategies aimed at disrupting the cell cycle in cancer cells without affecting normal tissue.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Gene Therapy (dn-CCNG1) | Delta-Receptor Therapeutics, Espy Bio | Osteosarcoma, Pancreatic Cancer, Solid Tumors | Functional expression verification (Need high-purity CCNG1 WT and mutant control proteins) |
| siRNA / RNAi | Academic Institutes, Biotech Startups | Colorectal Cancer, Chemoresistant Breast Cancer | Specific knockdown validation (Need sequence-verified siRNA and stable cell lines) |
| Small Molecule Inhibitors | Preclinical Discovery Stages | p53-mutant Cancers, Refractory Tumors | Protein-Protein Interaction (PPI) screening (Need low-endotoxin recombinant CCNG1 and MDM2/PP2A proteins) |